Characterization of In Vitro Glucuronidation Clearance of a Range of Drugs in Human Kidney Microsomes: Comparison with Liver and Intestinal Glucuronidation and Impact of Albumin

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Drug Metabolism And Disposition

• Publication date

  2012-04-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/dmd.111.043984PMID 22275465PMCID PMC3310423
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clarke’s Analysis of Drugs and Poisons

  2018cited by this paper
• Renal Distribution Volumes of Indocyanine Green , [ 5 " Cr ] EDTA , and 24 Na in Man during Acute Renal Failure after Shock

  2013cited by this paper
• Goodman & Gilman's The pharmacological basis of therapeutic

  2013cited by this paper
• Simultaneous Assessment of Uptake and Metabolism in Rat Hepatocytes: A Comprehensive Mechanistic Model

  2012cited by this paper
• Simultaneous Absolute Protein Quantification of Transporters, Cytochromes P450, and UDP-Glucuronosyltransferases as a Novel Approach for the Characterization of Individual Human Liver: Comparison with mRNA Levels and Activities

  2012influential reference
• Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography-tandem mass spectrometry.

  2012influential reference
• Absolute Quantification and Differential Expression of Drug Transporters, Cytochrome P450 Enzymes, and UDP-Glucuronosyltransferases in Cultured Primary Human Hepatocytes

  2012cited by this paper
• Quantification of Human Uridine-Diphosphate Glucuronosyl Transferase (UGT) 1A Isoforms in Liver, Intestine and Kidney using nanoLC-MS/MS

  2012cited by this paper
• Bovine Serum Albumin Decreases Km Values of Human UDP-Glucuronosyltransferases 1A9 and 2B7 and Increases Vmax Values of UGT1A9

  2011cited by this paper
• Immunohistochemical expression of conjugating UGT1A‐derived isoforms in normal and tumoral drug‐metabolizing tissues in humans

  2011cited by this paper
• A Novel Method for the Immunoquantification of UDP-Glucuronosyltransferases in Human Tissue

  2011cited by this paper
• Human Pharmacokinetic Prediction of UDP-Glucuronosyltransferase Substrates with an Animal Scale-Up Approach

  2011cited by this paper
• The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers

  2011cited by this paper
• Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system

  2010cited by this paper
• Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data

  2010cited by this paper
• Prediction of Human Metabolic Clearance from In Vitro Systems: Retrospective Analysis and Prospective View

  2010cited by this paper
• On the excretion of p-aminohippuric acid through the kidneys.

  2009cited by this paper
• Prediction of Drug Clearance by Glucuronidation from in Vitro Data: Use of Combined Cytochrome P450 and UDP-Glucuronosyltransferase Cofactors in Alamethicin-Activated Human Liver Microsomes

  2009cited by this paper
• Mixed-Effects Modeling of the Influence of Midazolam on Propofol Pharmacokinetics

  2009cited by this paper
• Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs.

  2009influential reference
• Quantitative Analysis of UDP-Glucuronosyltransferase (UGT) 1A and UGT2B Expression Levels in Human Livers

  2009cited by this paper
• Characterization of the Binding of Drugs to Human Intestinal Fatty Acid Binding Protein (IFABP): Potential Role of IFABP as an Alternative to Albumin for in Vitro-in Vivo Extrapolation of Drug Kinetic Parameters

  2009influential reference
• The maximum tubular excretion of diodrast in the normal human kidney.

  2009cited by this paper
• Relative Importance of Intestinal and Hepatic Glucuronidation—Impact on the Prediction of Drug Clearance

  2009cited by this paper
• Determination of mRNA Expression of Human UDP-Glucuronosyltransferases and Application for Localization in Various Human Tissues by Real-Time Reverse Transcriptase-Polymerase Chain Reaction

  2009cited by this paper
• The “Albumin Effect” and Drug Glucuronidation: Bovine Serum Albumin and Fatty Acid-Free Human Serum Albumin Enhance the Glucuronidation of UDP-Glucuronosyltransferase (UGT) 1A9 Substrates but Not UGT1A1 and UGT1A6 Activities

  2008influential reference
• Drug metabolism enzyme expression and activity in primary cultures of human proximal tubular cells.

  2008influential reference
• Population Pharmacokinetics of Intravenous, Intramuscular, and Intranasal Naloxone in Human Volunteers

  2008cited by this paper
• Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 670 Drug Compounds

  2008cited by this paper
• Pharmacokinetics of mycophenolate mofetil and its glucuronide metabolites in healthy volunteers.

  2008cited by this paper
• Drug Lipophilicity and Microsomal Protein Concentration as Determinants in the Prediction of the Fraction Unbound in Microsomal Incubations

  2008cited by this paper
• The UDP-Glucuronosyltransferase 2B7 Isozyme Is Responsible for Gemfibrozil Glucuronidation in the Human Liver

  2007cited by this paper
• Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver.

  2007cited by this paper
• Binding of Inhibitory Fatty Acids Is Responsible for the Enhancement of UDP-Glucuronosyltransferase 2B7 Activity by Albumin: Implications for in Vitro-in Vivo Extrapolation

  2007influential reference
• Human Renal Cortical and Medullary UDP-Glucuronosyltransferases (UGTs): Immunohistochemical Localization of UGT2B7 and UGT1A Enzymes and Kinetic Characterization of S-Naproxen Glucuronidation

  2007influential reference
• Prediction of total propofol clearance based on enzyme activities in microsomes from human kidney and liver

  2006influential reference
• PREDOMINANT CONTRIBUTION OF OATP1B3 TO THE HEPATIC UPTAKE OF TELMISARTAN, AN ANGIOTENSIN II RECEPTOR ANTAGONIST, IN HUMANS

  2006cited by this paper
• Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes.

  2006influential reference
• In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises.

  2006cited by this paper
• AN INVESTIGATION OF HUMAN AND RAT LIVER MICROSOMAL MYCOPHENOLIC ACID GLUCURONIDATION: EVIDENCE FOR A PRINCIPAL ROLE OF UGT1A ENZYMES AND SPECIES DIFFERENCES IN UGT1A SPECIFICITY

  2005cited by this paper
• GLUCURONIDATION OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS: IDENTIFYING THE ENZYMES RESPONSIBLE IN HUMAN LIVER MICROSOMES

  2005cited by this paper
• New application of a subcellular fractionation method to kidney and testis for the determination of conjugated linoleic acid in selected cell organelles of healthy and cancerous human tissues

  2005cited by this paper
• Bioavailability of diclofenac potassium at low doses.

  2005cited by this paper
• IDENTIFICATION OF THE UDP-GLUCURONOSYLTRANSFERASE ISOFORMS INVOLVED IN MYCOPHENOLIC ACID PHASE II METABOLISM

  2005cited by this paper
• UDP-glucuronosyltransferases and clinical drug-drug interactions.

  2005influential reference
• Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases.

  2005cited by this paper
• DETERMINATION OF DRUG GLUCURONIDATION AND UDP-GLUCURONOSYLTRANSFERASE SELECTIVITY USING A 96-WELL RADIOMETRIC ASSAY

  2005cited by this paper
• Human Kidneys Play an Important Role in the Elimination of Propofol

  2005influential reference
• Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil.

  2004cited by this paper
• The pharmacokinetics of diclofenac sodium following intravenous and oral administration

  2004cited by this paper
• Glucuronidation of carboxylic acid containing compounds by UDP-glucuronosyltransferase isoforms.

  2004cited by this paper
• Relationships Between Total and Unbound Propofol in Plasma and CSF During Continuous Drug Infusion

  2004cited by this paper
• Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7.

  2004influential reference
• Prediction of Human Drug Clearance from in Vitro and Preclinical Data Using Physiologically Based and Empirical Approaches

  2004cited by this paper
• Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia).

  2004cited by this paper
• Glucuronidation of oxidized fatty acids and prostaglandins B1 and E2 by human hepatic and recombinant UDP-glucuronosyltransferases Published, JLR Papers in Press, July 1, 2004. DOI 10.1194/jlr.M400103-JLR200

  2004influential reference
• Mixed-effects Modeling of the Influence of Alfentanil on Propofol Pharmacokinetics

  2004cited by this paper
• The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants.

  2004cited by this paper
• The effect of incubation conditions on the enzyme kinetics of udp-glucuronosyltransferases.

  2003cited by this paper
• HPLC investigation of free and bound propofol in human plasma and cerebrospinal fluid.

  2003cited by this paper
• Influence of Age and Cytochrome P450 2C9 Genotype on the Steady-State Disposition of Diclofenac and Celecoxib

  2003cited by this paper
• In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance.

  2002influential reference
• In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine.

  2002cited by this paper
• In Vivo Higher Glucuronidation of Mycophenolic Acid in Male Than in Female Recipients of a Cadaveric Kidney Allograft and Under Immunosuppressive Therapy With Mycophenolate Mofetil

  2001cited by this paper
• Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes

  2001cited by this paper
• Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac.

  2001cited by this paper
• The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism*†

  2001influential reference
• Organ weight in 684 adult autopsies: new tables for a Caucasoid population.

  2001cited by this paper
• Evidence for significant differences in microsomal drug glucuronidation by canine and human liver and kidney.

  2001cited by this paper
• The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes.

  2001influential reference
• Pharmacokinetics of Orally and Intravenously Administered Telmisartan in Healthy Young and Elderly Volunteers and in Hypertensive Patients

  2000cited by this paper
• Human UDP-glucuronosyltransferases: metabolism, expression, and disease.

  2000cited by this paper
• In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin.

  2000influential reference
• Absorption, Metabolism, and Excretion of Intravenously and Orally Administered [14C]Telmisartan in Healthy Volunteers

  2000cited by this paper
• Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine.

  2000cited by this paper
• Studies on the substrate specificity of human intestinal UDP- lucuronosyltransferases 1A8 and 1A10.

  1999cited by this paper
• Analyzing Rich Data Using Different Methods Provided by NONMEM: Pharmacokinetics of Telmisartan Following Intravenous Infusion to Healthy Volunteers

  1999cited by this paper
• Clinical Pharmacokinetics of Mycophenolate Mofetil

  1998cited by this paper
• Pharmacokinetics and Pharmacodynamics of Propofol in a New Solvent

  1997cited by this paper
• Pharmacokinetics and Bioavailability of Mycophenolate Mofetil in Healthy Subjects after Single‐Dose Oral and Intravenous Administration

  1996cited by this paper
• Extrahepatic glucuronidation of propofol in man: possible contribution of gut wall and kidney

  1996cited by this paper
• High molecular weight phospholipase A2 and fatty acids in human colon tumours and associated normal tissue.

  1996cited by this paper
• Reproducibility of human kidney perfusion and volume determinations with electron beam computed tomography.

  1996cited by this paper
• Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics.

  1995cited by this paper
• Blood Distribution of Mycophenolic Acid

  1994cited by this paper
• Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance.

  1994cited by this paper
• Measurement of normal renal artery blood flow: cine phase-contrast MR imaging vs clearance of p-aminohippurate.

  1993cited by this paper
• Physiological Parameters in Laboratory Animals and Humans

  1993cited by this paper
• Normal renal blood flow measurement using phase-contrast cine magnetic resonance imaging.

  1992cited by this paper
• Extrahepatic metabolism of propofol in man during the anhepatic phase of orthotopic liver transplantation.

  1992cited by this paper
• Glomerular number and size in relation to age, kidney weight, and body surface in normal man

  1992cited by this paper
• Geigy Scientific Tables

  1991cited by this paper
• Gemfibrozil absorption and elimination in kidney and liver disease

  1990cited by this paper
• PHARMACOKINETICS OF PROPOFOL INFUSIONS IN PATIENTS WITH CIRRHOSIS

  1990cited by this paper
• Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study.

  1990cited by this paper
• Reference values for resting blood flow to organs of man.

  1989cited by this paper
• Quantitative and pharmacokinetic analysis of naloxone in plasma using high-performance liquid chromatography with electrochemical detection and solid-phase extraction.

  1989cited by this paper
• Pharmacokinetics and Protein Binding of Propofol in Patients with Cirrhosis

  1988cited by this paper
• Disposition in male volunteers of a subanaesthetic intravenous dose of an oil in water emulsion of 14C-propofol.

  1988cited by this paper
• Extrahepatic metabolism of morphine occurs in humans.

  1988cited by this paper

• UDP-Glucuronosyl transferase mediated drug-drug interactions: An Industry perspective on recommended in vitro studies.

  2026cites this paper
• Important role of OATP in the liver disposition of ezetimibe and its consequent glucuronidation metabolite.

  2025cites this paper
• Pharmacokinetics of Binimetinib in Participants with Hepatic Impairment

  2025cites this paper
• Human and rat renal proximal tubule in vitro models for ADME applications

  2025cites this paper
• Pharmacokinetic comparison of a fixed-dose combination of telmisartan/rosuvastatin/ezetimibe/amlodipine 80/20/10/5 mg and a loose-dose combination of ezetimibe/rosuvastatin 10/20 mg and telmisartan/amlodipine 80/5 mg in healthy male subjects

  2025cites this paper
• Overlooked aspects of scaling enzyme activity through abundance across tissues and individuals: Insights from kcat measurements in matched liver and intestinal samples

  2025cites this paper
• Phase II metabolism in xenobiotic biotransformation: general mechanisms and the underestimated role of microbial systems

  2025cites this paper
• The Current State of Biotransformation Science – Industry Survey of In Vitro and In Vivo Practices, Clinical Translation, and Future Trends

  2024cites this paper
• Elucidating nonlinear pharmacokinetics of telmisartan: Integration of target‐mediated drug disposition and OATP1B3‐mediated hepatic uptake in a physiologically based model

  2024influential citation
• Albumin-Mediated Drug Uptake by Organic Anion Transporter 1/3 Is Real: Implications for the Prediction of Active Renal Secretion Clearance

  2024cites this paper
• Comparison of Relative Activity versus Relative Expression Factors (RAF versus REF) in Predicting Glucuronidation Mediated Drug Clearance Using Recombinant UGTs

  2024cites this paper
• Prediction of SPT-07A Pharmacokinetics in Rats, Dogs, and Humans Using a Physiologically-Based Pharmacokinetic Model and In Vitro Data

  2024cites this paper
• Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance.

  2023cites this paper
• Does Addition of Protein to Hepatocyte or Microsomal In Vitro Incubations Provide a Useful Improvement in In Vitro-In Vivo Extrapolation Predictability?

  2022cites this paper
• Examining Physiologically Based Pharmacokinetic Model Assumptions for Cross-Tissue Similarity of Activity per Unit of Enzyme: The Case Example of Uridine 5′-Diphosphate Glucuronosyltransferase

  2022influential citation
• Application of a gut-liver-on-a-chip device and mechanistic modelling to the quantitative in vitro pharmacokinetic study of mycophenolate mofetil.

  2022cites this paper
• The Functionality of UDP-Glucuronosyltransferase Genetic Variants and their Association with Drug Responses and Human Diseases

  2021cites this paper
• Enzyme Kinetics of Uridine Diphosphate Glucuronosyltransferases (UGTs).

  2021cites this paper
• Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study

  2021cites this paper
• Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Vadadustat, an Oral Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitor

  2021cites this paper
• Investigating the glucuronidation and sulfation pathways contribution and disposition kinetics of Bisphenol S and its metabolites using LC-MS/MS-based nonenzymatic hydrolysis method.

  2021cites this paper
• Recent developments in in vitro and in vivo models for improved translation of preclinical pharmacokinetics and pharmacodynamics data

  2021cites this paper
• Prediction of Drug Clearance from Enzyme and Transporter Kinetics.

  2021cites this paper
• Industrial approach to determine the relative contribution of seven major UGT isoforms to hepatic glucuronidation.

  2020cites this paper
• In vitro metabolism, reaction phenotyping, enzyme kinetics, CYP inhibition and induction potential of ataluren

  2020cites this paper
• In vitro-in vivo extrapolation of human hepatic and renal clearance

  2020cites this paper
• In Vitro to In Vivo Extrapolation of Metabolic Clearance for UGT Substrates Using Short-Term Suspension and Long-Term Co-cultured Human Hepatocytes

  2020cites this paper
• Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping.

  2020cites this paper
• In Vitro Characterization of Ertugliflozin Metabolism by UDP-Glucuronosyltransferase and Cytochrome P450 Enzymes

  2020cites this paper
• Evaluation of In Vitro Models for Assessment of Human Intestinal Metabolism in Drug Discovery

  2020cites this paper
• Main contribution of UGT1A1 and CYP2C9 in the metabolism of UR-1102, a novel agent for the treatment of gout

  2020cites this paper
• Absorption, Distribution, Metabolism, Excretion (ADME), Drug-drug interaction potential and Prediction of Human Pharmacokinetics of SUVN-G3031, a Novel Histamine 3 Receptor (H3R) inverse agonist in Clinical development for the treatment of Narcolepsy.

  2020cites this paper
• A Novel Physiologically Based Model of Creatinine Renal Disposition to Integrate Current Knowledge of Systems Parameters and Clinical Observations

  2020cites this paper
• Mechanisms of metabolism interaction between p-cresol and mycophenolic acid.

  2019cites this paper
• Human Efflux Transporters in Drug Disposition : in vitro Transport of Glucuronide Metabolites

  2019cites this paper
• High-dose naloxone, an experimental tool uncovering latent sensitisation: pharmacokinetics in humans.

  2019cites this paper
• Mechanistic Assessment of Extrahepatic Contributions to Glucuronidation of Integrase Strand Transfer Inhibitors

  2019cites this paper
• Utility of Chimeric Mice with Humanized Liver for Predicting Human Pharmacokinetics in Drug Discovery: Comparison with in Vitro-in Vivo Extrapolation and Allometric Scaling.

  2019cites this paper
• Modeling Exposure to Understand and Predict Kidney Injury.

  2019cites this paper
• Quantitative Prediction of Human Hepatic Clearance for P450 and Non-P450 Substrates from In Vivo Monkey Pharmacokinetics Study and In Vitro Metabolic Stability Tests Using Hepatocytes

  2019cites this paper
• A dual system platform for drug metabolism: Nalbuphine as a model compound.

  2019cites this paper
• Hepatic Organic Anion Transporting Polypeptide–Mediated Clearance in the Beagle Dog: Assessing In Vitro–In Vivo Relationships and Applying Cross-Species Empirical Scaling Factors to Improve Prediction of Human Clearance

  2018cites this paper
• The use of PBPK modeling across the pediatric age range using propofol as a case

  2018cites this paper
• The Ontogeny of UDP-glucuronosyltransferase Enzymes, Recommendations for Future Profiling Studies and Application Through Physiologically Based Pharmacokinetic Modelling

  2018cites this paper
• Assessing Herb–Drug Interactions of Herbal Products With Therapeutic Agents for Metabolic Diseases: Analytical and Regulatory Perspectives

  2018cites this paper
• An examination of protein binding and protein‐facilitated uptake relating to in vitro‐in vivo extrapolation

  2018cites this paper
• Physiologically-based pharmacokinetic predictions of intestinal BCRP-mediated drug interactions of rosuvastatin in Koreans

  2018cites this paper
• Influence of Stereochemistry on the Bioactivation and Glucuronidation of 4-Ipomeanol

  2018cites this paper
• Optimization of Experimental Conditions of Automated Glucuronidation Assays in Human Liver Microsomes Using a Cocktail Approach and Ultra-High Performance Liquid Chromatography–Tandem Mass Spectrometry

  2018cites this paper
• Particle Size Distribution Equivalency as Novel Predictors for Bioequivalence

  2018cites this paper
• Hepatic OATP-mediated clearance in the Beagle dog: assessing in vitro-in vivo relationships and applying cross species empirical scaling factors to improve prediction of human clearance

  2018cites this paper
• A Comparative Study of the Pharmacokinetics of Clozapine N-Oxide and Clozapine N-Oxide Hydrochloride Salt in Rhesus Macaques

  2018cites this paper
• Sandwich-Cultured Hepatocytes for Mechanistic Understanding of Hepatic Disposition of Parent Drugs and Metabolites by Transporter–Enzyme Interplay

  2018cites this paper
• LC–MS/MS method for the simultaneous quantification of intestinal CYP and UGT activity

  2018cites this paper
• Optimization of intestinal microsomal preparation in the rat: A systematic approach to assess the influence of various methodologies on metabolic activity and scaling factors

  2017cites this paper
• Small structural changes of the imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitors produce an improved safety profile.

  2017cites this paper
• The Inhibition of Hepatic and Renal Glucuronidation of p-Nitrophenol and 4-Methylumbelliferone by Oil Palm Empty Fruit Bunch Lignin and Its Main Oxidation Compounds

  2017cites this paper
• Retracted: Physiologically based pharmacokinetic predictions of intestinal BCRP‐mediated effect of telmisartan on the pharmacokinetics of rosuvastatin in humans

  2017cites this paper
• In vitro metabolism of the anti-inflammatory clerodane diterpenoid polyandric acid A and its hydrolysis product by human liver microsomes and recombinant cytochrome P450 and UDP-glucuronosyltransferase enzymes

  2017influential citation
• The Role of the Kidney in Drug Elimination: Transport, Metabolism, and the Impact of Kidney Disease on Drug Clearance

  2017cites this paper
• Species and Tissue Differences in β-Estradiol 17-Glucuronidation.

  2017cites this paper
• Unequivocal evidence supporting the segregated flow intestinal model that discriminates intestine versus liver first-pass removal with PBPK modeling.

  2017cites this paper
• Revisiting the Latency of Uridine Diphosphate-Glucuronosyltransferases (UGTs)—How Does the Endoplasmic Reticulum Membrane Influence Their Function?

  2017cites this paper
• Inhibition of cytochrome P450 enzymes by saturated and unsaturated fatty acids in human liver microsomes, characterization of enzyme kinetics in the presence of bovine serum albumin (0.1 and 1.0% w/v) and in vitro – in vivo extrapolation of hepatic clearance

  2017cites this paper
• Effect of hepatic drug transporter polymorphisms on the pharmacokinetics of mycophenolic acid in patients with severe renal dysfunction before renal transplantation

  2017cites this paper
• Microsomal and Cytosolic Scaling Factors in Dog and Human Kidney Cortex and Application for In Vitro-In Vivo Extrapolation of Renal Metabolic Clearance

  2017influential citation
• Bio-relevant characterisation of lipidic formulations and prediction of in vivo exposure

  2017cites this paper
• Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans

  2016cites this paper
• Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance

  2016cites this paper
• Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part II: Mechanistic Models and In Vitro-In Vivo Extrapolation

  2016cites this paper
• Propofol Pharmacokinetics and Estimation of Fetal Propofol Exposure during Mid-Gestational Fetal Surgery: A Maternal-Fetal Sheep Model

  2016cites this paper
• Key to Opening Kidney for In Vitro–In Vivo Extrapolation Entrance in Health and Disease: Part I: In Vitro Systems and Physiological Data

  2016cites this paper
• Novel minimal physiologically-based model for the prediction of passive tubular reabsorption and renal excretion clearance

  2016cites this paper
• Stereoselective Glucuronidation of Bupropion Metabolites In Vitro and In Vivo

  2016cites this paper
• In Vitro Drug Metabolism Using Liver Microsomes

  2016cites this paper
• A physiologically based pharmacokinetic model to predict the pharmacokinetics of highly protein‐bound drugs and the impact of errors in plasma protein binding

  2016cites this paper
• Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWG.

  2016cites this paper
• The Role of Extracellular Binding Proteins in the Cellular Uptake of Drugs: Impact on Quantitative In Vitro-to-In Vivo Extrapolations of Toxicity and Efficacy in Physiologically Based Pharmacokinetic-Pharmacodynamic Research.

  2016cites this paper
• Physiological scaling factors and mechanistic models for prediction of renal clearance from in vitro data

  2016influential citation
• Optimisation of in vitro methodology for drug metabolism studies to improve prediction of hepatic drug clearance

  2016cites this paper
• Simultaneous analysis of gemfibrozil, morphine, and its two active metabolites in different mouse brain structures using solid-phase extraction with ultra-high performance liquid chromatography and tandem mass spectrometry with a deuterated internal standard.

  2016cites this paper
• Scaling factors for the in vitro-in vivo extrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearance.

  2016cites this paper
• Synthesis and Characterization of a Novel Mycophenolic Acid-Quinic Acid Conjugate Serving as Immunosuppressant with Decreased Toxicity.

  2015cites this paper
• DMD065870 1468..1476

  2015cites this paper
• SYSTEM-DEPENDENT METABOLISM OF DRUGS BY CYTOCHROME P450: THE MECHANISTIC BASIS FOR WHY HUMAN LIVER MICROSOMES ARE SUPERIOR TO HUMAN HEPATOCYTES AT METABOLIZING MIDAZOLAM BUT INFERIOR AT METABOLIZING DESLORATADINE

  2015influential citation
• Discovery and Optimization of Imidazopyridine-Based Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2).

  2015cites this paper
• To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics

  2015cites this paper
• Inhibition of Human UDP-Glucuronosyltransferase Enzymes by Canagliflozin and Dapagliflozin: Implications for Drug-Drug Interactions

  2015cites this paper
• Cellular Asymmetric Catalysis by UDP-glucuronosyltransferase 1A8 Shows Functional Localization to the Basolateral Plasma Membrane*

  2015cites this paper
• Content and activity of human liver microsomal protein and prediction of individual hepatic clearance in vivo

  2015cites this paper
• A Translational Approach to Assess the Risk of Dietary Substance-Drug Interactions

  2015cites this paper
• Reaction Phenotyping: Advances in the Experimental Strategies Used to Characterize the Contribution of Drug-Metabolizing Enzymes

  2015cites this paper
• Chemoenzymatic Synthesis, Characterization, and Scale-Up of Milk Thistle Flavonolignan Glucuronides

  2015cites this paper
• Prediction of hepatic and intestinal glucuronidation using in vitro-in vivo extrapolation.

  2015cites this paper
• Understanding the Transport Properties of Metabolites: Case Studies and Considerations for Drug Development

  2014cites this paper
• Identification of saturated and unsaturated fatty acids released during microsomal incubations

  2014cites this paper
• Physiologically Based Pharmacokinetic Prediction of Telmisartan in Human

  2014cites this paper
• Recipient uridine 5'-diphospho-glucuronosyltransferase UGT1A9 c.98T>C variant determines transplanted kidney filtration rate.

  2014cites this paper
• Enzyme kinetics of uridine diphosphate glucuronosyltransferases (UGTs).

  2014cites this paper
• Microsoft Word-90329935-file00.docx

  2014influential citation